Clinical Trial Update: INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of INCAGN01876 in combination with immune therapies in advanced/metastatic cancers was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignancies

Drugs mentioned

• INCAGN01876

Snippet

Sponsor: Incyte Biosciences International Sàrl | Conditions: Advanced Malignancies, Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-22